

# Drug Policy

<b>Policy:</b>	<b>Qinlock (riporetinib)</b>	<b>Annual Review Date:</b> <b>06/18/2020</b>  <b>Last Revised Date:</b> <b>06/18/2020</b>
----------------	------------------------------	---

## OVERVIEW

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib (Gleevec), sunitinib (Sutent) and regorafenib (Stivarga). Qinlock is a broad-spectrum c-kit (KIT) and PDGFRA inhibitor. This medication has several warnings and precautions, including a recommendation to permanently discontinue therapy if the patient develops Grade 3 or 4 left ventricular systolic dysfunction. The FDA granted this application Priority Review and Fast Track designation, as well as Breakthrough Therapy designation. Qinlock also received Orphan Drug designation.

## POLICY STATEMENT

This policy involves the use of Qinlock. Prior authorization is recommended for pharmacy benefit coverage of Qinlock. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Qinlock as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Qinlock be prescribed by or in consultation with a physician who specializes in the condition being treated. In order to be considered for coverage, Qinlock must be prescribed by or in consultation with a hematologist, gastroenterologist, or oncologist. All approvals for initial therapy are provided for the initial approval duration noted below.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Qinlock is recommended in those who meet the following criteria:

1. **Advanced Gastrointestinal Stromal Tumors (GIST)**  
**Criteria.** *Patient must meet the following criteria*
  - A. The patient is 18 years of age or older; AND
  - B. The patient has received 3 or more prior kinase inhibitor therapies, including imatinib.
2. **Patients with another indication that is not listed but is cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation**  
**Criteria.** *Prescriber will provide specific diagnosis for documentation. Approve.*

# Drug Policy

### 3. Patient has been started on Qinlock

**Criteria.** *Approve for an indication or condition addressed as an approval in this document.*

#### **Initial Approval/ Extended Approval.**

A) *Initial Approval:* 1 year

B) *Extended Approval:* 1 year

---

#### **CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Qinlock has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### **Documentation Requirements:**

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

#### **REFERENCES**

1. Qinlock [prescribing information]. Waltham, MA: Deciphera Pharmaceuticals, LLC; May 2020.
2. The NCCN Drugs and Biologics Compendium. © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on 3 June 2020.
3. Ripretinib. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 20 May 2020. Accessed on 3 June 2020.